GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are the most effective obesity drugs ever developed, producing 15–22.5% total body weight loss in landmark trials. But the same evidence shows that roughly 70–80% of patients discontinue them within two years, and those who stop regain about two-thirds of the weight within a year. For India — where obesity prevalence is rising fast, BMI cutoffs are lower than Western standards, and almost no Indian-specific trial data exists — the honest verdict is that these drugs are powerful tools for the right patients, not a cost-free shortcut.
Last verified: 2026-08-02
- Semaglutide (Wegovy): ~15% mean weight loss at 68 weeks (STEP-1, NEJM 2021)
- Tirzepatide (Zepbound): ~20.9–22.5% at 72 weeks (SURMOUNT-1, NEJM 2022)
- SELECT trial: 20% reduction in major cardiovascular events over 3.9 years (NEJM 2023)
- Real-world persistence: only 27–43% of patients still on therapy at 12 months
- Weight regain after stopping: ~two-thirds of lost weight within 1 year (Diabetes Obes Metab 2022)
- India has no large-scale GLP-1 obesity trial; WHO Asian BMI cutoffs apply (≥23 overweight, ≥27.5 obese)
- Volatile facts: Pricing, availability, and regulatory status change often — last checked Aug 2026.
What Are GLP-1 Drugs and How Do They Work?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable — and in some cases oral — medications originally developed for type 2 diabetes that also produce significant weight loss. Semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity) mimic a naturally occurring gut hormone that signals fullness to the brain, slows stomach emptying, and stimulates insulin release in response to meals. The result is reduced appetite, earlier satiety, and — at clinical doses — double-digit percentage body weight loss.
Novo Nordisk's semaglutide received FDA approval for chronic weight management in 2021 (Wegovy, 2.4 mg weekly). Eli Lilly's tirzepatide — a dual GLP-1/GIP receptor agonist — received obesity approval in late 2023 (Zepbound). Both are administered as once-weekly subcutaneous injections. In India, semaglutide is available under the brand Ozempic (Novo Nordisk) and is regulated by the Central Drugs Standard Control Organization (CDSCO), requiring a prescription from a registered medical practitioner — ideally an endocrinologist or physician.
How Much Weight Do GLP-1 Drugs Actually Help You Lose?
The headline numbers from the pivotal trials are the best evidence we have, and they are impressive — but they come with important caveats.
The STEP-1 trial (NEJM 2021) tested semaglutide 2.4 mg weekly in 1,961 adults with obesity (BMI ≥30, or ≥27 with comorbidity) over 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% for placebo — a 12.5 percentage-point difference. Nearly two-thirds of treated patients lost at least 10% of their body weight.
The SURMOUNT-1 trial (NEJM 2022) tested tirzepatide at three doses (5, 10, 15 mg) in 2,539 adults over 72 weeks. The highest dose produced a mean 22.5% weight loss (20.9% across all doses) versus 3.1% for placebo. Roughly 91% of patients on the 15 mg dose lost at least 5% of body weight, and 63% lost at least 20%.
| Drug | Trial | Duration | Mean Weight Loss | Placebo | Source |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP-1 | 68 weeks | 14.9% | 2.4% | NEJM 2021 |
| Tirzepatide 15 mg | SURMOUNT-1 | 72 weeks | 22.5% | 3.1% | NEJM 2022 |
| Tirzepatide (all doses) | SURMOUNT-1 | 72 weeks | 20.9% | 3.1% | NEJM 2022 |
The critical caveat: these are trial populations with structured support, diet counseling, and regular monitoring. Real-world results are typically lower because adherence wanes, lifestyle support is thinner, and insurance coverage runs out.
What Happens When You Stop Taking GLP-1 Drugs?
This is the question the debate often glosses over — and the answer is the single strongest argument against treating GLP-1s as a quick fix. A 2022 study published in Diabetes, Obesity and Metabolism tracked patients who stopped semaglutide after one year and found they regained approximately two-thirds of their lost weight within 12 months of discontinuation. A separate Oxford-led analysis confirmed the pattern: without continued medication, appetite signaling reverts to baseline, and the body's metabolic adaptation makes weight maintenance harder than the initial loss.
The implication is stark: GLP-1 drugs are not a one-time treatment that resets your weight. They appear to be a chronic medication — take them indefinitely (or commit to a sustained lifestyle intervention afterward) or expect substantial regain. This is the pharmacological reality that much of the social-media discourse about "Ozempic" omits.
Why this matters for India specifically: at a cost of ₹15,000–₹25,000 per month for branded semaglutide, indefinite treatment is unaffordable for the vast majority of Indian patients. If the drug only works while you take it, and most patients eventually stop, the cost-benefit calculus looks very different than the trial headlines suggest.
What Does the SELECT Trial Tell Us About Heart Health?
The SELECT trial (NEJM 2023, PMID 37952131) was the landmark cardiovascular outcomes study. It enrolled 17,604 adults aged ≥45 with BMI ≥27 and preexisting cardiovascular disease (but no diabetes) across 41 countries, randomizing them to weekly semaglutide 2.4 mg or placebo for up to five years (median follow-up 39.8 months).
The result: semaglutide produced a 20% reduction in major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. All three components contributed to the reduction. This was the first time a weight-loss medication demonstrated cardiovascular benefit in patients without diabetes, and it led to the FDA's 2024 expansion of Wegovy's label to include cardiovascular risk reduction.
A 2025 prespecified analysis in The Lancet added a nuance: only about 33% of the cardiovascular benefit was mediated through waist circumference reduction, meaning most of the cardioprotective effect appears to come from mechanisms beyond fat loss. This suggests GLP-1 drugs are not merely weight-loss tools but potentially disease-modifying agents.
What Is the Real-World Dropout Rate for GLP-1 Drugs?
Trial adherence does not survive contact with the real world. Multiple real-world persistence studies paint a starkly different picture from the clinical trials:
A 2024 analysis of U.S. pharmacy claims data found that only 27–43% of patients initiating GLP-1 therapy for weight management remained on treatment at 12 months. By 24 months, persistence dropped below 20% in some cohorts. The top reasons for discontinuation were cost and insurance coverage gaps, gastrointestinal side effects (nausea, vomiting, diarrhea), and the perception that results did not justify the ongoing expense.
This 70–80% dropout rate at two years matters enormously because:
- The trials that show 15–22% weight loss assume continued use — the real-world average loss is substantially lower because most people are no longer taking the drug.
- Those who stop not only stop losing but, as studies show, rapidly regain.
- The drugs' cardiovascular and metabolic benefits likewise require ongoing use — there is no evidence that a short course provides lasting protection.
Why Do BMI Cutoffs Matter for India?
India's obesity problem looks different from America's — and using the wrong BMI threshold masks it.
The World Health Organization recommends lower BMI cutoffs for Asian populations: ≥23 kg/m² for overweight (versus ≥25 for the general WHO standard) and ≥27.5 kg/m² for obesity (versus ≥30). This is because at the same BMI, Asians carry more visceral fat and develop metabolic complications — type 2 diabetes, hypertension, cardiovascular disease — at lower body weights than Caucasian populations.
Using the standard ≥30 cutoff, India's obesity prevalence looks modest. Using Asian-specific cutoffs, the picture changes dramatically. National Family Health Survey (NFHS-5, 2019–21) data showed that 22.9% of Indian men and 24.0% of Indian women were overweight or obese using Asian cutoffs — with rates much higher in urban areas. India is also experiencing rapid growth in diabetes prevalence, with an estimated 101 million people living with diabetes (ICMR 2023) — many driven by obesity-related insulin resistance.
This means the population that might benefit from GLP-1 therapy in India is potentially larger than headline obesity rates suggest — and that the question of who should take these drugs, at what BMI, and for how long, is more urgent than most public-health discourse acknowledges.
What Are the Side Effects and Risks?
The most common side effects are gastrointestinal: nausea (affecting ~44% of patients in STEP-1), diarrhea (~30%), vomiting (~24%), and constipation. These are typically worst during dose escalation and often subside, but they contribute significantly to the real-world dropout rate.
Rarer but more serious concerns include:
- Pancreatitis — warning added to semaglutide labeling; incidence is low but elevated versus placebo.
- Gallbladder events — gallstones and cholecystitis appear more frequent with rapid weight loss, though this risk overlaps with weight loss itself.
- Muscle loss — GLP-1-associated weight loss includes lean body mass, not just fat. The STEP trials showed roughly 30–40% of total weight lost was lean tissue, raising concerns about sarcopenia (muscle loss) especially in older adults.
- Gastroparesis — because GLP-1 slows stomach emptying, there are case reports of severe gastroparesis, particularly in patients with preexisting diabetic neuropathy.
- "Ozempic face" — a colloquial description of the facial volume loss some patients experience after rapid fat loss; not a clinical diagnosis but a real cosmetic concern.
The long-term safety profile beyond 5 years is limited. The SELECT trial provides the longest controlled data at ~4 years, and no novel long-term safety signals emerged — but 4 years is not a lifetime, and these drugs are being prescribed indefinitely.
Is Obesity in India Really a Problem Worth Treating With Drugs?
The counter-argument — articulated forcefully in the YouTube debate that prompted this article — is that obesity in India is being medicalized for profit, and that the real drivers are dietary and lifestyle changes that drugs merely paper over.
The evidence actually supports a middle ground:
Obesity is a genuine public-health crisis in India. The IARC (WHO's cancer research agency) identifies 13 cancers associated with overweight and obesity — including cancers of the colon, breast (postmenopausal), kidney, pancreas, liver, and endometrium. CDC data shows these 13 cancers account for 40% of all cancers diagnosed in the U.S. each year. India's rising obesity trajectory — particularly abdominal obesity — is driving parallel increases in diabetes, hypertension, and cardiovascular disease.
But lifestyle intervention remains the first-line treatment. The Diabetes Prevention Program (DPP) showed that intensive lifestyle intervention reduced diabetes incidence by 58% over 3 years — versus 31% for metformin. The Look AHEAD trial demonstrated that sustained lifestyle intervention in adults with type 2 diabetes produced meaningful weight loss, improved fitness, and reduced cardiovascular risk factors over a decade of follow-up. Lifestyle works — but it requires sustained effort, and the challenge is that most people struggle to sustain it, which is exactly the gap GLP-1 drugs fill.
The honest synthesis: for most Indian patients with obesity (using Asian cutoffs), lifestyle intervention should remain the first step. GLP-1 drugs are a powerful second-line option for those who have tried and failed behavioral change, particularly those with obesity-related complications (diabetes, hypertension, established cardiovascular disease). They are not a replacement for lifestyle change — they are a complement, and ideally a temporary one paired with building sustainable habits.
What About Cost and Access in India?
In India, Ozempic (semaglutide) costs approximately ₹15,000–₹25,000 per month, depending on dose and source — putting it among the most expensive routine medications in a country where per-capita healthcare spending is under ₹5,000 per year. Tirzepatide (Mounjaro) is not yet widely available in India as of mid-2026. Generic semaglutide is not legally available until the Novo Nordisk patent expires (expected late 2020s in most jurisdictions, though India's patent landscape is more complex).
This cost reality drives the dropout problem. If the drugs only work while taken indefinitely, and most Indians cannot afford indefinite treatment, the question shifts from "do these drugs work?" to "who in India can actually benefit from them given the economic constraints?" — and the answer, at current prices, is a narrow slice of the population.
CDSCO regulation requires a prescription from a registered medical practitioner. Endocrinologists and bariatric physicians are the appropriate prescribers. Black-market and online procurement without medical supervision carry significant risk — particularly because dose escalation should be medically monitored.
What This Means for You
If you are an Indian adult concerned about your weight, here is the practical framework:
- Check your BMI using Asian cutoffs. A BMI ≥23 means you are classified as overweight by WHO Asian standards, and ≥27.5 means obesity. Do not compare yourself to Western BMI thresholds — your metabolic risk is higher at a lower weight.
- Start with lifestyle. Diet modification (reduce processed foods and sugar), regular physical activity, and sleep optimization remain the first-line treatment. They work for the majority of patients if sustained.
- If lifestyle has not worked after 6 months of genuine effort — especially if you have prediabetes, hypertension, or a family history of cardiovascular disease — talk to an endocrinologist about GLP-1 therapy. This is where the drugs' risk-benefit may genuinely favor you.
- If you start a GLP-1 drug, have a maintenance plan before you begin. Most patients will need to stop eventually — whether due to cost, side effects, or coverage limits. Without a lifestyle strategy to carry forward, you are likely to regain. Use the medication window to build the habits that sustain weight loss without it.
- Never obtain GLP-1 drugs without medical supervision. Dose titration, side effect management, and monitoring require a physician — self-prescription risks serious harm.
FAQ
Q: Are GLP-1 drugs like Ozempic safe for long-term use? A: The SELECT trial provides controlled safety data out to ~4 years (median 39.8 months) and found no novel long-term safety signals beyond the known gastrointestinal side effects. However, data beyond 5 years is not yet available, and rare risks like pancreatitis remain under monitoring. The drugs are considered reasonably safe for chronic use under medical supervision.
Q: How much does Ozempic cost in India? A: Branded semaglutide (Ozempic) costs approximately ₹15,000–₹25,000 per month in India, depending on the dose and pharmacy. Prices may change — this was last checked in August 2026. Generic semaglutide is not legally available in India until patent expiration, expected in the late 2020s.
Q: Do you regain weight after stopping GLP-1 drugs? A: Yes — studies show patients typically regain about two-thirds of their lost weight within 12 months of discontinuing semaglutide. This is why GLP-1 drugs are generally considered a chronic medication, not a one-time treatment. The strategy of using them temporarily while building lifestyle habits is logical but not well-studied yet.
Q: Can GLP-1 drugs prevent heart attacks? A: The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 20% over 3.9 years in adults with obesity and preexisting cardiovascular disease. This benefit was independent of the amount of weight lost. The FDA expanded Wegovy's label in 2024 to include cardiovascular risk reduction.
Q: What BMI qualifies for GLP-1 treatment in India? A: Using WHO Asian cutoffs, BMI ≥27.5 (obese) or ≥23 (overweight) with weight-related comorbidities like diabetes, hypertension, or sleep apnea may qualify. CDSCO regulates semaglutide as a prescription drug — an endocrinologist or physician must prescribe it. Each patient's eligibility should be assessed individually.
Q: Are there non-drug alternatives that work as well as GLP-1s? A: Bariatric surgery (gastric bypass, sleeve gastrectomy) produces 20–30% sustained weight loss in patients with severe obesity, exceeding GLP-1 results. For moderate obesity, intensive lifestyle intervention (as in the DPP and Look AHEAD trials) produces 5–10% sustained weight loss and meaningfully reduces diabetes and cardiovascular risk. Lifestyle works for many — it is the sustainability that is hard.
Discussion
0 comments